Evidence map›Paper›PMID 24951278›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

NS19504: a novel BK channel activator with relaxing effect on bladder smooth muscle spontaneous phasic contractions.

Bernhard Nausch, Frederik Rode, Susanne Jørgensen, Antonio Nardi, Mads P G Korsgaard, Charlotte Hougaard, Adrian D Bonev, William D Brown, Tino Dyhring, Dorte Strøbæk and 5 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. BK Channels Regulate LPS-induced CCL-2 Release from Human Pulmonary Endothelial Cells.American journal of respiratory cell and molecular biology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Bernhard NauschNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Frederik RodeNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Susanne JørgensenNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Antonio NardiNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Mads P G KorsgaardNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Charlotte HougaardNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Adrian D BonevNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
William D BrownNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Tino DyhringNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Dorte StrøbækNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Søren-Peter OlesenNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Palle ChristophersenNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Morten GrunnetNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Mark T NelsonNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.).
Lars C B RønnNeuroSearch A/S, Ballerup, Denmark (F.R., S.J., A.N., M.P.G.K., C.H., W.D.B., T.D., D.S., S.-P.O., P.C., M.G., L.C.B.R.); University of Vermont, Department of Pharmacology, Burlington, Vermont (B.N., A.D.B., M.T.N.); and Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom (M.T.N.) lcbr@lundbeck.com.
University of Manchester · GBNeuroSearch (Denmark) · DKUniversity of Vermont · US

Funding

Impact of SAH on Parenchymal Arterioles and Neurovascular CouplingP01HL095488 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI BONEV, ADRIAN · 2010 to 2014
$11.4M
REGULATION OF CEREBRAL ARTERY DILATIONR01HL044455 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI NELSON, MARK T · 1991 to 2010
$3.9M
Ca2+ Sparks and Urinary Bladder Smooth Muscle ExcitabilityR37DK053832 · NIDDK · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI NELSON, MARK T · 2008 to 2017
$3.4M
CA++ SPARKS &URINARY BLADDER SMOOTH MUSCLE EXCITABILITYR01DK053832 · NIDDK · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI NELSON, MARK T · 1998 to 2006
$2.0M
NHLBI NIH HHS 1P01-HL095488NHLBI NIH HHS HL044455NHLBI NIH HHS P01 HL095488NHLBI NIH HHS R01 HL044455NIDDK NIH HHS R37 DK053832NIDDK NIH HHS R37-DK053832
6 · The paper itself

Abstract

Large-conductance Ca(2+)-activated K(+) channels (BK, KCa1.1, MaxiK) are important regulators of urinary bladder function and may be an attractive therapeutic target in bladder disorders. In this study, we established a high-throughput fluorometric imaging plate reader-based screening assay for BK channel activators and identified a small-molecule positive modulator, NS19504 (5-[(4-bromophenyl)methyl]-1,3-thiazol-2-amine), which activated the BK channel with an EC50 value of 11.0 ± 1.4 µM. Hit validation was performed using high-throughput electrophysiology (QPatch), and further characterization was achieved in manual whole-cell and inside-out patch-clamp studies in human embryonic kidney 293 cells expressing hBK channels: NS19504 caused distinct activation from a concentration of 0.3 and 10 µM NS19504 left-shifted the voltage activation curve by 60 mV. Furthermore, whole-cell recording showed that NS19504 activated BK channels in native smooth muscle cells from guinea pig urinary bladder. In guinea pig urinary bladder strips, NS19504 (1 µM) reduced spontaneous phasic contractions, an effect that was significantly inhibited by the specific BK channel blocker iberiotoxin. In contrast, NS19504 (1 µM) only modestly inhibited nerve-evoked contractions and had no effect on contractions induced by a high K(+) concentration consistent with a K(+) channel-mediated action. Collectively, these results show that NS19504 is a positive modulator of BK channels and provide support for the role of BK channels in urinary bladder function. The pharmacologic profile of NS19504 indicates that this compound may have the potential to reduce nonvoiding contractions associated with spontaneous bladder overactivity while having a minimal effect on normal voiding.

Indexed as

AnimalsCalcium Channel AgonistsFemaleGuinea PigsHEK293 CellsHumansLarge-Conductance Calcium-Activated Potassium ChannelsMaleMuscle ContractionMuscle RelaxationOrgan Culture TechniquesUrinary BladderCalcium Channel AgonistsLarge-Conductance Calcium-Activated Potassium Channels

Identifiers

PMID24951278
PMCPMC4152884
OpenAlexW2136813723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.